AIDS CLINICAL TRIALS UNIT

描述(改编自申请者的摘要)： 宾夕法尼亚州(宾夕法尼亚州)ACTU由位于 宾夕法尼亚大学(HUP)和退伍军人分部 行政医院计划于1999年1月开业。这代表了 宾夕法尼亚大学ACTU自1998年7月以来的结构变化 杰斐逊大学(TJU)作为一个亚单位被删除。有了这个 重组，资金已重新分配，从而能够增加七个 宾夕法尼亚大学的科学家到由弗里德曼博士组成的核心研究小组 (首席调查员)，MacGregor(机会性感染)，Frank (抗逆转录病毒疗法)、Kolson(神经艾滋病/痴呆症)和Pmerantz (病机)，最后一个是我们小组的顾问。新的 科学家包括格罗斯博士(坚持治疗)、福尔摩斯博士(质量 生命)、Rader(代谢和脂蛋白异常)、Kimmel(危险因素 心脏病)、Weissman(艾滋病毒免疫学)、Grossman(神经成像) 艾滋病痴呆症)和Jemmott(招募和保留妇女和 少数族裔)。 宾夕法尼亚大学的HIV临床计划包括在HUP护理的750名患者，435人 在VAH，在长老会医疗中心250。宾夕法尼亚州立大学的医生 为艾滋病毒患者提供初级保健服务，这提供了一种联系 服务提供者和临床研究单位设在身份证司内。这个 门诊人群的人口结构与#年疫情的人口结构相匹配。 费城；因此，非裔美国人、妇女和吸毒者 (特别是在增加VAH的情况下)可以随时访问临床 审判。大约60%的研究患者来自诊所 而40%的推荐来自于在整个过程中执业的医生 特拉华河谷，使许多患者能够获得艾滋病毒临床试验。这个 研究人员拥有基础和以病人为中心的临床资格证书 研究。

DESCRIPTION (adapted from the applicant's abstract): The University of Pennsylvania (Penn) ACTU consists of the main unit located at the Hospital of the University of Pennsylvania (HUP) and a subunit at the Veterans Administration Hospital (VAH) scheduled to open January 1999. This represents a change in the structure of the Penn ACTU since July 1998 when Thomas Jefferson University (TJU) was removed as a subunit. With this reorganization, funding has been redistributed enabling the addition of seven Penn scientists to the core group of investigators consisting of Drs. Friedman (Principal Investigator), MacGregor (Opportunistic Infections), Frank (antiretroviral therapy), Kolson (neuroAIDS/dementia), and Pomerantz (pathogenesis), the last serves as a consultant to our group. The new scientists include Drs. Gross (adherence to therapy), Holmes (quality of life), Rader (metabolic and lipoprotein abnormalities), Kimmel (risk factors for cardiac disease), Weissman (HIV immunology), Grossman (neuroimaging for AIDS dementia) and Jemmott (recruitment and retention of women and minorities). The HIV clinical program at Penn includes 750 patients cared for at HUP, 435 at the VAH, and 250 at Presbyterian Medical Center. Penn ID physicians are primary care providers for the HIV patients, which provides a link between the providers and the clinical research unit housed within the ID division. The demographics of the clinic population match those of the epidemic in Philadelphia; therefore, African Americans, women and IDU subjects (particularly with the addition of the VAH) have ready access to clinical trials. Approximately 60 percent of study patients come from the clinics while 40 percent are referred from physicians practicing throughout the Delaware Valley, enabling many patients to access HIV clinical trials. The investigators have credentials in basic and patient-oriented clinical research.